Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosis
$45 million clinical program funded by the Defense Threat Reduction Agency- Trial initiates clinical development effort in support of ACG-701 as a treatment for multiple life-threatening orphan pulmonary diseases, including cystic fibrosis RALEIGH-DURHAM, NC – June 15, 2022 – Aceragen, Inc., a clinical-stage biopharmaceutical company developing therapies for rare pulmonary and rheumatic diseases with high unmet
